ENDSULIN, Inc. is a pre-clinical stage gene therapy company focused on advancing its lead clinical candidate to treat Diabetes Mellitus. ENDSULIN’s novel technology aims to give millions greater euglycemic control by combining the extensively tested AAV8 platform with a patented liver-directed gene construct. The construct contains a regulatory element to precisely regulate insulin expression in response to fluctuating glucose levels in the blood.

NEWS

PROGRESS

Foundational research

ENDSULIN has proven efficacy and durability in hundreds of rodents.

Dr. Sollinger’s research, conducted at UW-Madison, has been published in several peer-reviewed scientific research journals, including PLOS ONE in June 2013.

Read it now

This video shows two treated rats, an experimental control and an untreated rat (the smallest animal).

INCREDIBLE IMPACT

0 people
30 million people struggle with Type 1 diabetes in developed countries worldwide. It’s also one of the fastest-growing diseases.

Not only could this treatment realistically reach millions of patients with Type 1 diabetes — early signs show it could potentially treat Type 2 diabetes, too.

0 x
as many patients suffer with type 2 diabetes

2-4 insulin injections

every day, on average, to manage the disease. ►
Proper management takes constant monitoring and restrictive lifestyle changes.

Fewer than 2k patients

receive pancreas transplants each year, worldwide. ►
This procedure is the only long-term diabetes treatment available now, but there are limited donors available.

Leading cause

of kidney failure, blindness, and vascular disease. ►

Even with diligent daily management, many patients still experience severe complications.